P4HA2 promotes tumor progression and is transcriptionally regulated by SP1 in colorectal cancer

References

• Walker C, Mojares E, Del Río Hernández A. Role of extracellular matrix in development and cancer progression. Int J Mol Sci. 2018 Oct 4. 19(10):3028. doi:10.3390/ijms19103028.
   PubMed Web of Science ®Google Scholar
• Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim AV, Hebestreit HF, Mukherji M, Schofield CJ. et al. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001 Apr 20. 292(5516):468–12. doi:10.1126/science.1059796.
   PubMed Web of Science ®Google Scholar
• Feng GX, Li J, Yang Z, Zhang SQ, Liu YX, Zhang WY, Ye LH, Zhang XD. Hepatitis B virus X protein promotes the development of liver fibrosis and hepatoma through downregulation of miR-30e targeting P4HA2 mRNA. Oncogene. 2017 Dec 14. 36(50):6895–905. doi:10.1038/onc.2017.291.
   PubMed Web of Science ®Google Scholar
• Toss MS, Miligy IM, Gorringe KL, AlKawaz A, Khout H, Ellis IO, Green AR, Rakha EA. Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS). Br J Cancer. 2018 Dec. 119(12):1518–26. doi:10.1038/s41416-018-0337-x.
   PubMed Web of Science ®Google Scholar
• Li Q, Wang Q, Zhang Q, Zhang J, Zhang J. Collagen prolyl 4-hydroxylase 2 predicts worse prognosis and promotes glycolysis in cervical cancer. Am J Transl Res. 2019 Nov 15. 11(11):6938–51.
   PubMed Web of Science ®Google Scholar
• Xiong G, Deng L, Zhu J, Rychahou PG, Xu R. Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition. BMC Cancer. 2014 Jan 2. 14(1):1. doi:10.1186/1471-2407-14-1.
   PubMedGoogle Scholar
• Cao Y, Han Q, Li J, Jia Y, Zhang R, Shi H. P4HA2 contributes to cervical cancer progression via inducing epithelial-mesenchymal transition. J Cancer. 2020;11(10):2788–99. doi:10.7150/jca.38401.
   PubMed Web of Science ®Google Scholar
• Ribatti D, Tamma R, Annese T. Epithelial-mesenchymal transition in cancer: a historical overview. Transl Oncol. 2020 Apr 22. 13(6):100773. doi:10.1016/j.tranon.2020.100773.
   PubMed Web of Science ®Google Scholar
• Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 2006 Sep 1. 66(17):8319–26. doi:10.1158/0008-5472.CAN-06-0410.
   PubMed Web of Science ®Google Scholar
• Elzamly S, Badri N, Padilla O, Dwivedi AK, Alvarado LA, Hamilton M, Diab N, Rock C, Elfar A, Teleb M. et al. Epithelial-mesenchymal transition markers in breast cancer and pathological responseafter neoadjuvant chemotherapy. Breast Cancer (Auckl). [2018 Aug 1]. 12:1178223418788074. doi:10.1177/1178223418788074.
   Google Scholar
• Wang T, Fu X, Jin T, Zhang L, Liu B, Wu Y, Xu F, Wang X, Ye K, Zhang W. et al. Aspirin targets P4HA2 through inhibiting NF-κB and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma. EBioMedicine [Internet]. 2019 Jul [accessed 2019 Jul 12]. https://linkinghub.elsevier.com/retrieve/pii/S2352396419304293.
   Google Scholar
• Jiang W, Jin Z, Zhou F, Cui J, Wang L, Wang L. High co-expression of Sp1 and HER-2 is correlated with poor prognosis of gastric cancer patients. Surg Oncol. 2015 Sep. 24(3):220–25. doi:10.1016/j.suronc.2015.05.004.
   PubMed Web of Science ®Google Scholar
• Safe S, Abbruzzese J, Abdelrahim M, Hedrick E. Specificity protein transcription factors and cancer: opportunities for drug development. Cancer Prev Res (Phila). 2018 Jul. 11(7):371–82. doi:10.1158/1940-6207.CAPR-17-0407.
   PubMed Web of Science ®Google Scholar
• Gao Y, Gan K, Liu K, Xu B, Chen M. SP1 expression and the clinicopathological features of tumors: a meta-analysis and bioinformatics analysis. Pathol Oncol Res. 2021;27:581998. doi:10.3389/pore.2021.581998.
   PubMed Web of Science ®Google Scholar
• Beishline K, Azizkhan-Clifford J. Sp1 and the ‘hallmarks of cancer’. FEBS J. 2015 Jan. 282(2):224–58. doi:10.1111/febs.13148.
   PubMed Web of Science ®Google Scholar
• Bossé GD, Simard MJ. A new twist in the microRNA pathway: not dicer but Argonaute is required for a microRNA production. Cell Res. 2010 Jul. 20(7):735–37. doi:10.1038/cr.2010.83.
   PubMed Web of Science ®Google Scholar
• Wang M, Zhang L, Liu Z, Zhou J, Pan Q, Fan J, Zang R, Wang L. AGO1 may influence the prognosis of hepatocellular carcinoma through TGF-β pathway. Cell Death Dis. 2018 Feb 27. 9(3):324. doi:10.1038/s41419-018-0338-y.
   PubMedGoogle Scholar
• Qi HH, Ongusaha PP, Myllyharju J, Cheng D, Pakkanen O, Shi Y, Lee SW, Peng J, Shi Y. Prolyl 4-hydroxylation regulates Argonaute 2 stability. Nature. 2008 Sep 18. 455(7211):421–24. doi:10.1038/nature07186.
   PubMed Web of Science ®Google Scholar
• Wu C, So J, Davis-Dusenbery BN, Qi HH, Bloch DB, Shi Y, Lagna G, Hata A. Hypoxia potentiates MicroRNA-mediated gene silencing through posttranslational modification of Argonaute2. Mol Cell Biol. 2011 Dec 1. 31(23):4760–74. doi:10.1128/MCB.05776-11.
   PubMed Web of Science ®Google Scholar
• Agarwal S, Behring M, Kim HG, Bajpai P, Chakravarthi BVSK, Gupta N, Elkholy A, Al Diffalha S, Varambally S, Manne U. Targeting P4HA1 with a small molecule inhibitor in a colorectal cancer PDX model. Transl Oncol [Internet]. 2020 Mar 18;13(4):100754. [accessed 2020 Sep 20]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082635/.
   PubMed Web of Science ®Google Scholar
• Luo R, Zhuo Y, Du Q, Xiao R. POU2F2 promotes the proliferation and motility of lung cancer cells by activating AGO1. BMC Pulm Med. 2021 Apr 8. 21(1):117. doi:10.1186/s12890-021-01476-9.
   PubMed Web of Science ®Google Scholar
• Li L, Yu C, Gao H, Li Y. Argonaute proteins: potential biomarkers for human colon cancer. BMC Cancer. 2010 Dec. 10(1):38. doi:10.1186/1471-2407-10-38.
   PubMedGoogle Scholar
• Liu Y, Wang G, Yang Y, Mei Z, Liang Z, Cui A, Wu T, Liu C-Y, Cui L. Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelial–mesenchymal transition and metastasis in a YAP-independent manner. Oncogene. 2016 May. 35(21):2789–800. doi:10.1038/onc.2015.342.
   PubMed Web of Science ®Google Scholar
• Xu W, Sheng Y, Guo Y, Huang Z, Huang Y, Wen D, Liu C-Y, Cui L, Yang Y, Du P. et al. Increased IGF2BP3 expression promotes the aggressive phenotypes of colorectal cancer cells in vitro and vivo. J Cell Physiol. 2019 Aug. 234(10):18466–79. doi:10.1002/jcp.28483.
   PubMed Web of Science ®Google Scholar